Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy - PubMed (original) (raw)
Randomized Controlled Trial
. 2008 Mar 15;14(6):1767-74.
doi: 10.1158/1078-0432.CCR-07-4122.
Martina Lehnert, Anh Huynh, Raimund Jakesz, Christian Singer, Sigurd Lax, Walter Schippinger, Otto Dietze, Richard Greil, Wolfgang Stiglbauer, Werner Kwasny, Renate Grill, Michael Stierer, Michael F X Gnant, Martin Filipits; Austrian Breast and Colorectal Cancer Study Group
Collaborators, Affiliations
- PMID: 18347178
- DOI: 10.1158/1078-0432.CCR-07-4122
Randomized Controlled Trial
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy
Margaretha Rudas et al. Clin Cancer Res. 2008.
Abstract
Purpose: The objective of our study was to determine the clinical relevance of cyclin D1 expression in hormone receptor-positive breast cancer patients who were treated with tamoxifen-based therapy.
Experimental design: We assessed expression of cyclin D1 in surgical specimens of breast carcinoma by means of immunohistochemistry. Patients had been enrolled in either Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 05 or ABCSG Trial 06 and received tamoxifen as part of their adjuvant treatment. Overall survival and relapse-free survival were analyzed with Cox models adjusted for clinical and pathologic factors.
Results: Cyclin D1 was expressed in 140 of 253 (55%) tumors of ABCSG Trial 05 and in 569 of 948 (60%) tumors of ABCSG Trial 06. Expression of cyclin D1 was associated with poor outcome in both cohorts. Overall survival was significantly shorter in patients with cyclin D1-positive tumors compared with patients with cyclin D1-negative tumors [adjusted hazard ratio (HR) for death (ABCSG Trial 05), 2.47; 95% confidence interval (95% CI), 1.08-5.63; P = 0.03; adjusted HR for death (ABCSG Trial 06), 1.78; 95% CI, 1.36-2.34; P < 0.0001]. Relapse-free survival was also shorter in patients with cyclin D1-positive tumors than in patients with cyclin D1-negative tumors [adjusted HR for relapse (ABCSG Trial 05), 2.73; 95% CI, 1.50-4.96; P = 0.001; adjusted HR for relapse (ABCSG Trial 06), 1.52; 95% CI, 1.14-2.04; P = 0.005].
Conclusion: Cyclin D1 expression is an independent poor prognostic factor in women with early-stage, hormone receptor-positive breast cancer who received adjuvant tamoxifen-based therapy.
Similar articles
- High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.
Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R, Filipits M. Pohl G, et al. J Clin Oncol. 2003 Oct 1;21(19):3594-600. doi: 10.1200/JCO.2003.02.021. J Clin Oncol. 2003. PMID: 14512390 - Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF; Austrian Breast and Colorectal Cancer Study Group. Filipits M, et al. Clin Cancer Res. 2009 Sep 15;15(18):5888-94. doi: 10.1158/1078-0432.CCR-09-0728. Epub 2009 Sep 1. Clin Cancer Res. 2009. PMID: 19723645 - Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, et al. Gasparini G, et al. Clin Cancer Res. 1995 Feb;1(2):189-98. Clin Cancer Res. 1995. PMID: 9815973 - Adjuvant systemic therapy for breast cancer. Issues for primary care physicians.
Berkowitz LD, Love N. Berkowitz LD, et al. Postgrad Med. 1995 Oct;98(4):85-8, 91, 94. Postgrad Med. 1995. PMID: 7567725 Review. - Adjuvant therapy in early breast cancer.
Chittoor SR, Swain SM. Chittoor SR, et al. Am Fam Physician. 1991 Aug;44(2):453-62. Am Fam Physician. 1991. PMID: 1858602 Review.
Cited by
- Low levels of sex hormone-binding globulin predict an increased breast cancer risk and its underlying molecular mechanisms.
Zhao S, Gu J, Tian Y, Wang R, Li W. Zhao S, et al. Open Life Sci. 2024 Feb 8;19(1):20220822. doi: 10.1515/biol-2022-0822. eCollection 2024. Open Life Sci. 2024. PMID: 38465341 Free PMC article. Review. - Comprehensive multi-level expression profiling of key biomarkers in breast cancer patients.
Zia T, Bangfan L, Nadeem A, Hussain A, Abdel-Maksoud MA, Zakri AM, Bashir MK, Ali M, Jabeen N, Jamil M, Al-Qahtani WH, Almanaa TN. Zia T, et al. Am J Transl Res. 2023 Oct 15;15(10):6058-6070. eCollection 2023. Am J Transl Res. 2023. PMID: 37969199 Free PMC article. - Prognostic Significance of Cyclin D1 Expression in Small Intestinal Adenocarcinoma.
Jun SY, Hong SM, Jang KT. Jun SY, et al. Cancers (Basel). 2023 Oct 18;15(20):5032. doi: 10.3390/cancers15205032. Cancers (Basel). 2023. PMID: 37894399 Free PMC article. - Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Alves CL, Ehmsen S, Terp MG, Portman N, Tuttolomondo M, Gammelgaard OL, Hundebøl MF, Kaminska K, Johansen LE, Bak M, Honeth G, Bosch A, Lim E, Ditzel HJ. Alves CL, et al. Nat Commun. 2021 Aug 25;12(1):5112. doi: 10.1038/s41467-021-25422-9. Nat Commun. 2021. PMID: 34433817 Free PMC article. - High Expression of Cyclin D1 is an Independent Marker for Favorable Prognosis in Middle Eastern Breast Cancer.
Siraj AK, Parvathareddy SK, Annaiyappanaidu P, Ahmed SO, Siraj N, Tulbah A, Al-Dayel F, Ajarim D, Al-Kuraya KS. Siraj AK, et al. Onco Targets Ther. 2021 May 19;14:3309-3318. doi: 10.2147/OTT.S309091. eCollection 2021. Onco Targets Ther. 2021. PMID: 34040395 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials